Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine

被引：0
|
作者：
Ailani, J. [1 ]
Gandhi, P. [2 ]
Lalla, A. [3 ]
Singh, R. B. Halker [4 ]
McAllister, P. [5 ]
Smith, J. H. [6 ]
Dabruzzo, B. [2 ]
Chalermpalanupap, N. [2 ]
Nahas, S. J. [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] AbbVie, Madison, NJ USA
[3] AbbVie, Irvine, CA USA
[4] Mayo Clin, Scottsdale, AZ USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] AbbVie, N Chicago, IL USA
[7] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P051
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine
    Schwedt, T. J.
    Lipton, R. B.
    Ailani, J.
    Silberstein, S. D.
    Tassorelli, C.
    Guo, H.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 159 - 160
  • [42] Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China
    Tian, Shuo
    Yang, Yuping
    Tan, Shenglan
    Luo, Jiani
    Yang, Chuanyu
    Liu, Qiao
    Guo, Yujin
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [43] Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
    Gisondi, Paolo
    Geat, Davide
    Maurelli, Martina
    Degli Esposti, Luca
    Bellinato, Francesco
    Girolomoni, Giampiero
    VACCINES, 2022, 10 (05)
  • [44] Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2-4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
    Reuter, U.
    Lalla, A.
    Sacco, S.
    Holle-Lee, D.
    Pozo-Rosich, P.
    Nagy, K.
    Luo, L.
    Carr, K.
    Gandhi, P.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [45] Decrease in body weight with once-daily atogepant for the preventive treatment of migraine: A post hoc analysis
    Dodick, D. W.
    Hay, D. L.
    Walker, C. S.
    Goadsby, P. J.
    Ailani, J.
    Severt, L.
    Finnegan, M.
    Ma, J.
    Guo, H.
    Trugman, J. M.
    HEADACHE, 2022, 62 : 96 - 97
  • [46] Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
    Holle-Lee, D.
    Gandhi, P.
    Reuter, U.
    Ailani, J.
    Lipton, R. B.
    Nagy, K.
    Liu, Y.
    Carr, K.
    Stokes, J.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [47] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
  • [48] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    Goadsby, P.
    Lipton, R.
    Reuter, U.
    Guo, H.
    Schwefel, B.
    Boinpally, R.
    McCusker, E.
    Yu, S. Yun
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [49] Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
    Diener, Hans-Christoph
    Tassorelli, Cristina
    Dodick, David W.
    Silberstein, Stephan D.
    Lipton, Richard B.
    Ashina, Messoud
    Becker, Werner J.
    Ferrari, Michel D.
    Goadsby, Peter J.
    Pozo-Rosich, Patricia
    Wang, Shuu-Jiun
    Houle, Timothy T.
    van den Hoek, Thomas C.
    Martinelli, Daniele
    Terwindt, Gisela M.
    CEPHALALGIA, 2020, 40 (10) : 1026 - 1044
  • [50] Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
    Irimia, Pablo
    Santos-Lasaosa, Sonia
    Pozo-Rosich, Patricia
    Leira, Rogelio
    Pascual, Julio
    Lainez, Jose Miguel
    FRONTIERS IN NEUROLOGY, 2024, 15
12345